Nanobiotix S.A. (NBTX) has presented Part 1 data from its randomized Phase 2 CONVERGE study at the 2026 European Society for Radiotherapy and Oncology (ESTRO) meeting. The trial, sponsored by Johnson & Johnson, is evaluating JNJ-1900 (NBTXR3), a nanoparticle-based radioenhancer, in patients with stage III inoperable non-small cell lung cancer (NSCLC).
Trial Design
The study enrolled patients with stage III NSCLC who were not eligible for surgery. NBTXR3 was administered as a one-time intratumoral injection, followed by concurrent chemoradiotherapy and durvalumab consolidation. The goal was to assess feasibility, safety, and early efficacy signals.
Results Presented
The company reported that intratumoral injection of NBTXR3 was feasible and safe. Among seven patients who completed treatment, the overall response rate was 85.7%, with a complete response rate of 57.1% and a disease control rate of 100%. Importantly, no progressive disease was observed, and responses appeared to deepen over time. About NBTXR3
NBTXR3 is a first-in-class radioenhancer made of hafnium oxide nanoparticles. Once injected into a tumor and activated by radiotherapy, it is designed to intensify tumor cell destruction and potentially stimulate long-term immune memory. The therapy has already shown proof-of-concept in soft tissue sarcoma and is being studied across multiple solid tumors.
NBTX has traded between $3.64 and $57.14 over the past year. The stock closed Friday's trading (May 15, 2026) at $51.50, down 6.48%. In pre-market trading, the stock is at $53.68, up 4.23%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.